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Abstract
Microvascular pericytes are of key importance in neoformation of blood vessels, in stabilization of newly formed vessels as
well as maintenance of angiostasis in resting tissues. Furthermore, pericytes are capable of differentiating into pro-fibrotic
collagen type I producing fibroblasts. The present study investigates the effects of the histone deacetylase (HDAC) inhibitor
valproic acid (VPA) on pericyte proliferation, cell viability, migration and differentiation. The results show that HDAC
inhibition through exposure of pericytes to VPA in vitro causes the inhibition of pericyte proliferation and migration with no
effect on cell viability. Pericyte exposure to the potent HDAC inhibitor Trichostatin A caused similar effects on pericyte
proliferation, migration and cell viability. HDAC inhibition also inhibited pericyte differentiation into collagen type I
producing fibroblasts. Given the importance of pericytes in blood vessel biology a qPCR array focusing on the expression of
mRNAs coding for proteins that regulate angiogenesis was performed. The results showed that HDAC inhibition promoted
transcription of genes involved in vessel stabilization/maturation in human microvascular pericytes. The present in vitro
study demonstrates that VPA influences several aspects of microvascular pericyte biology and suggests an alternative
mechanism by which HDAC inhibition affects blood vessels. The results raise the possibility that HDAC inhibition inhibits
angiogenesis partly through promoting a pericyte phenotype associated with stabilization/maturation of blood vessels.
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Introduction
Microvascular pericytes are cells of mesenchymal origin situated
juxtaposition to the endothelial layer in the microvasculature i.e.
capillaries, venules and small arterioles. They are continuous with
the vascular basement membrane. Pericytes have a central role in
the structural and functional integrity of the microvascular bed in
resting tissues. Their equivalents in larger vessels are smooth muscle
cells [1]. During development and in adult activated tissues they are
important modulators of the angiogenic process where they regulate
vascular regression, pruning and vessel maturation during tissue
remodeling [2]. Pericytes also play a role in promoting platelet
aggregation [3]. Thus pericytes, in addition to endothelial cells,
must also be tightly controlled in order to maintain tissue
homeostasis, optimize tissue repair and regeneration. Their role in
tissue repair is further highlighted by their ability to act as
multipotent mesenchymal stem cells. In vivo, pericytes have been
shown to differentiate into smooth muscle cells and myofibroblasts,
and in vitro to osteoblasts, adipocytes and chondroblast [4,5].
Based on studies on human pathological conditions and animal
models,weand othershave proposed that pericytesininflammatory
conditions including wound healing in adult tissues become
activated and expand into pro-fibrotic connective tissue cells,
indicating that these microvascular cells play a central role in tissue
fibrosis [6–13]. We have developed methods to isolate and
propagate pericytes from placenta and neonatal skin which has
enabled the study of pericyte biology and in particular their
differentiation into collagen type I producing fibroblasts, a process
that spontaneously takes place when pericytes are cultured in the
presence of 10% fetal calf serum (FCS) [6–9].
Epigenetic inheritance represents heritable patterns in gene
expression caused by mechanisms other than changes in underlying
DNA sequences [14]. Thus, non-genetic factors can cause genes to
behave differently opening up possibilities such as modifying the
phenotype of congenital and acquired diseases [14]. Furthermore,
epigenetic mechanisms are believed to modify the progeny of stem/
progenitor cells as well as affect the phenotypes of individual
specialized cells and maintain these phenotypes over several rounds
of cell division thus constituting a mechanism by which cells have
‘‘memory’’ [15,16]. The molecular basis of epigenetics is complex
but includes DNA methylation and post-translational modifications
of histones such as acetylation and methylation. These DNA and
histone modifications affect chromatin structure, thereby regu-
lating gene expression [17]. The state of histone acetylation is a
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(HATs) and histone deactetylases (HDACs), acetylating and
deacetylating histones, respectively [17]. Acetylation generally
leads to transcriptionally active chromatin while deacetylation
results in transcriptional silencing [18,19]. Valproic acid (VPA) is
an aliphatic acid compound that has been used for decades as a
medication to treat epilepsy and as a mood stabilizer in bipolar
disorder [18,20]. VPA is one among several HDAC inhibitors
[21,22]. VPA is also recognized for its teratogenic effects in
humans [22,23].
HDAC inhibition results in hyperacetylation of histones [20]
and affects gene expression, which in turn influences cellular
proliferation, differentiation, apoptosis and migration [18,20] as
well as more complex multi-cellular processes such as angiogenesis
[24–29] and fibrosis [25,30–32]. Thus, HDAC inhibition has
therefore been postulated to affect genetic perturbations as occurs
in for instance congenital and neoplastic disease [17,20]. Studies
have shown potential beneficial effects of HDAC inhibition in a
wide array of diseases including cystic fibrosis, malignancies,
myelofibrosis and neurodegenerative diseases such as Alzheimers
and Huntingtons disease [17,20].
Several in vitro and in vivo studies have shown that HDAC
inhibition is anti-angiogenic [24–29]. The present in vitro study is
the first investigation into the biological consequences of HDAC
inhibition in well-defined primary human microvascular peri-
cytes. HDAC inhibition reduced pericyte proliferation and
inhibition of migration without significantly affecting cell
viability. The differentiation of pericytes into pro-fibrotic
connective tissue cells was reduced by VPA suggesting a novel
pericyte based process of how HDAC inhibition may perturb
fibrosis. Furthermore, a limited qPCR microarray approach
focusing on mRNAs coding for proteins involved in angiogenesis
was performed in freshly isolated human pericytes revealing
expression patterns of angiogenic mRNAs and the potential effect
that HDAC inhibition may have on these expression patterns.
The overall results in the present study suggest that HDAC
inhibition of pericytes promotes a phenotype involved in vessel
stabilization/maturation [24–29].
Results
VPAs effect on cytotoxicity, cell viability and histone 4
acetylation in human pericytes
Microvascular pericytes with a phenotype consistent with
pericytes in vivo were isolated from full-term human placentas as
previously described [6–8]. To investigate pericyte sensitivity to
VPA, a characterization of cell cytotoxicity and viability/density
was performed. Cytotoxic effect was observed when pericytes were
exposed to concentrations of VPA exceeding 5 mM (Figure 1A; t-
test p,0.001). A reduction in the proportion of viable cells
compared to cell density was also first observed at these
concentrations (Figure 1B). Subsequent exposures were therefore
conducted at lower concentrations.
VPA has been reported to inhibit HDAC and thereby increase
histone acetylation in several cell types [21,22]. To determine if
VPA had HDAC inhibitory effects in pericytes, we assessed the
levels of acetylated histone H4 in pericytes exposed to 1 mM
VPA and non-treated control (NTC) pericytes. NTC pericytes
displayed weak histone H4 acetylation, whereas levels of
acetylation were increased already at 0.5 hours and were
maintained for up to 7 days in pericytes continuously exposed
to 1 mM VPA (Figure 1C).
Effect of HDAC inhibition on proliferation and cell
viability in human pericytes
We investigated if VPA is able to influence pericyte prolifera-
tion. EdU incorporation as a measure of cells entering the S-phase
of proliferation was significantly reduced by approximately 70% in
pericytes after a 24 h exposure to 1 mM VPA compared to NTC
pericytes (Figure 2A; t-test p,0.001). Similar results were achieved
Figure 1. Cytotoxic effect of VPA on human pericytes. (A) Cytotoxicity index based on nuclear fragmentation and lysosomal pH in human
pericytes exposed to 1–15 mM VPA for 3 days. (B) Cell density and viable cell measurement in human pericytes exposed to 1–15 mM VPA for 3 days.
(C) VPA effects on histone 4 acetylation (H4ac) in human pericytes exposed for different time periods to 2 mM VPA. Mean 6 standard deviation (SD),
n=4. T-test * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0024954.g001
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3H-tymidine incorporation, also an indicator of cells
entering the S-phase of proliferation (data not shown). No
significant further reduction in pericyte proliferation was observed
using higher concentrations of VPA. The reduction in pericyte
proliferation and viability when exposed to Trichostatin A (TSA),
another compound that inhibits HDAC, was of a similar
magnitude when compared to VPA. 2-Et-4-Me-Penta (Penta) is
a VPA analogue, which has no inhibitory effect on HDACs
[33–35]. When pericytes were exposed to Penta there was a
statistically significant reduction of pericyte proliferation by
approximately 30% compared to NTC pericytes (t-test p,0.01).
The reduction of proliferation in pericytes exposed to VPA or
TSA was more pronounced than that seen in cells exposed to
Penta (Figure 2A).
Previous studies have shown that HDAC inhibition leads to an
increase in cell death [18,20]. Propidium iodide (PI) was used as an
indicator of cell viability to investigate if HDAC inhibition of
pericytes affected the number of viable cells. No significant
differences in the percentage of dead/dying cells were observed
when pericytes were exposed for 24 h (Figure 2B) and 72 h (data
not shown) to VPA, TSA or the VPA analogue Penta when
compared to NTC pericytes.
To investigate the effects of VPA on pericyte proliferation over
several cell cycles, cells were labeled with CFDA-SE and further
cultured in the presence or absence of VPA for one week. At the 7-
day time point CFDA-SE retention was measured by flow
cytometry. The principle of the CFDA-SE assay is that the
amount of CFDA-SE is distributed evenly between daughter cells
following each generation/cell-division [36]. This analysis dem-
onstrated that the percentage of cells retaining CFDA-SE was
significantly increased in pericytes exposed to 1 mM and 5 mM
VPA at the 7-day time point compared to NTC (Figure 2C; t-test
p,0.05).
VPAs effect on migration of human pericytes
The effect of VPA on migration of pericytes was investigated in
a 20 h wound scratch cell migration assay [37] (Figure 3A). The
migration score was quantified as outlined in Materials and
Methods. Migration was significantly inhibited when pericytes
were exposed to 3 mM VPA (t-test p,0.01). No significant effect
on pericyte migration was observed at lower VPA concentrations
(Figure 3B). The VPA analogue Penta lacking HDAC inhibitory
activity had no significant effect on pericyte migration (Figure 3B).
Pericytes exposed to 10 nM TSA, a more potent HDAC inhibitor,
was significantly reduced compared to NTC pericytes (Figure 3B;
t-test p,0.05). This effect was not seen at 5 nM TSA.
VPAs effect on differentiation of human pericytes to
collagen type I producing fibroblasts
We have previously reported that pericytes differentiate into
procollagen type I producing fibroblasts in 10% FCS culture
conditions and that this differentiation process can be monitored
by the expression patterns of several protein markers [6–8]. The
relative expression of the number of cells expressing each marker
was quantified by flow cytometry and compared to NTC
pericytes (Figure 4A–D). VPA exposure at a concentration of 1
or 2 mM, during a 72-hour incubation period inhibited this
differentiation process based on the observed shift in marker
expression profiles compared to NTC pericytes (Figure 4A–D).
The relative number of cells expressing a-SMA, a marker
expressed in both pericytes and fibroblasts [9,38–40], were not
affected by VPA exposure (Figure 4A). VPA exposure signifi-
cantly increased (t-test p,0.01) the relative number of cells
expressing the mesenchymal stem cell marker CD146 (M-CAM)
[41,42] (Figure 4B). A significantly reduced number of cells
expressed the fibroblast surface protein’’ (FSP) [43] (Figure 4C;
t-test p,0.01) and procollagen type I [41–43] (Figure 4D; t-test
p,0.001) after VPA exposure.
Figure 2. Effect of VPA on human pericyte proliferation and
cell viability. (A) Proliferation rate i.e. % of cells entering S-phase
depicted by EDU incorporation in pericytes exposed to VPA, TSA or
Penta for 24 hours compared to NTC pericytes (100%). (B) Cell viability
i.e. % of cells positive for PI in pericytes exposed to VPA, TSA or Penta
for 24 hours compared to NTC pericytes. (C) Flow cytometric analysis of
CFDA-SE labeled pericytes exposed to 1 and 5 mM of VPA for 7 days
compared to NTC. CFDA-SE retention reflects a lower rate of
proliferation in pericytes. Mean 6 SD, in A and C n=6, in B n=4.
T-test * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0024954.g002
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wound scratch assay was studied. (A) Representative images of pericyte cultures in the wound scratch assay at t=0 and at t=20 h (white dotted
lines designate the borders of the wound scratch), exposed to 2 mM VPA and NTC pericytes. (B) Migration scores calculated as outlined in materials
and methods were determined in pericyte cultures exposed to different concentrations of VPA, TSA or Penta. Mean 6 SD, n=4. T-test * p,0.05,
** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0024954.g003
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angiogenesis in human pericytes
Considering the role of pericytes in angiogenesis, we next
analyzed the effect of VPA on a group of angiogenesis related genes
after three days of exposure to 2 mM VPA. Pericytes derived from
four separate placentas were analyzed with qPCR angiogenesis
arrays (Figure 5, for a list of abbreviations see Table S1). A total
of 14 genes (,18%) were significantly affected in pericytes
exposed to VPA compared to NTC pericytes (Table 1; t-test
p,0.05). An analysis of the data shows that VPA exposure in
general increases gene expression of angiogenesis associated genes
in pericytes (Figure 5A). Only 4 genes showed a tendency towards
down regulation but did not reach statistical significance (data not
shown). The data was normalized against three housekeeping
genes HPRT1, RPL13A and GAPDH (Figure 5B). A clear
separation between the VPA exposed pericytes and NTC
pericytes can be seen in the principal component analysis
(PCA) (Figure 5C). The top significant genes were searched
against the protein interaction database STRING version 8.3
(http://string.embl.de/) for protein-protein interaction networks
and the results visualized using the Cytoscape software (Figure 5D).
STRING interactions are based on different sources such as
annotated experimental data, co-expression, and text mining. A
high STRING interaction score (1.0 being the maximum score)
between genes/proteins correlates with multiple sources of
evidence. This analysis identified additional genes/proteins,
which were not included in the qPCR angiogenesis array but
are known to interact with the proteins, which mRNAs were
Figure 4. Effect of VPA on human pericyte differentiation. Quantification by flow cytometry, displayed as ‘‘relative expression’’ compared to
NTC pericytes (1.0) within ‘‘sets’’ of 10.000 analyzed cells, of protein markers that define different stages of the differentiation process from
microvascular pericyte to collagen type I producing fibroblast in pericyte cultures exposed to 1 mM and 2 mM VPA compared to NTC. (A) a-SMA, (B)
CD146, (C) FSP, (D) procollagen type I. Mean 6 SD, n=3. T-test * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0024954.g004
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separate protein interaction clusters. The interaction analysis
indicates that a number of the significant VPA induced genes are
directly or indirectly connected to a TGF-b and TIMP associated
network, which themselves were significantly upregulated (Figure
5D and Table 1). In NTC pericytes, of the 84 genes studied, a
relatively large proportion (36 genes ,43%), included in the
qPCR angiogenesis array had Ct values .35 (14 genes ,17%;
Figure 5E and F) which is the cut-off limit recommended by the
manufacturers, or were not detected at all (22 genes ,26%;
Figure 5E and F). In pericytes exposed to VPA compared
to NTC pericytes 13 genes (,15%) were induced i.e. had a
CT value of less than 35 when exposed to VPA (Figure 5F). Only
one genes expression (PDGF-A) was extinguished by VPA
exposure.
Discussion
The aim of this study was to probe if HDAC inhibition has
any effect on human microvascular pericytes with regards to
proliferation, cell viability, migration and differentiation into pro-
fibrotic connective tissue cells in vitro. Furthermore, given the
growing importance of the role of the pericyte in the regulation of
the vasculature and the process of angiogenesis focus was directed
towards potential modifications of expression patterns of mRNAs
coding for proteins known to be involved in the angiogenic process
in pericytes in response to HDAC inhibition.
The effect of HDAC inhibition on pericyte proliferation was
investigated. Inhibition of pericyte proliferation was seen already
at a concentration of 1 mM VPA. Although the VPA analogue
Penta which lacks HDAC inhibitory effects had a statistically
Figure 5. Effect of VPA on expression of angiogenesis related genes in human pericytes. Characterization of changes in angiogenesis
gene expression in pericytes exposed to 2 mM VPA over three days compared to NTC using a qPCR angiogenesis microarray. (A) Scatter plot based
on transformed DCt values for NTC and VPA for each gene. Each axis is in the log
10 scale. The letter H represents the expression of housekeeping
genes. (B) The average DCt value for the three housekeeping genes (HPRT1, RPL13A and GAPDH) used in the qPCR analysis. (C) Combination of
unsupervised hierarchical clustering and principal component analysis. The dendrogram shows that NTC and VPA samples separate from each other.
The first component (PC1) explains 43.5% of the variation in the data and separates NTC from VPA samples. NTC sample 4 differs somewhat from the
other NTC (see PC2). (D) Network analysis of the most significant angiogenesis genes using data exported from the STRING database and visualized in
Cytoscape. Edges between nodes are based on different levels of evidence. Solid lines are based on a high combined STRING confidence level (.0.9)
whereas dotted lines are ,0.9. The color of the nodes/genes is based on their p-value from the pair-wise comparison between NTC and VPA samples.
Gray colored nodes represent genes not analyzed in this experiment and do therefore not possess any p-values. (E) Percentage of the total included
84 genes that were expressed in each Ct value range in VPA and NTC pericytes. (F) Shifts in Ct value ranges in each individual gene in VPA compared
to NTC pericytes.
doi:10.1371/journal.pone.0024954.g005
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approximate that observed in pericytes exposed to VPA suggesting
that the anti-proliferative effect was to a large extent due to VPAs
ability to inhibit HDACs. However, a certain effect on pericyte
proliferation due to the ‘‘off target effects’’ of VPA cannot be
excluded. The notion that it is HDAC inhibition that is responsible
for the effects seen on pericyte proliferation were further supported
by experiments using TSA, another more potent HDAC inhibitor,
which had similar anti-proliferative effects on pericytes when
compared to VPA. The CFDA-SE incorporation experiments
show that VPA, in a concentration dependent manner, limits the
expansion of the pericyte population over the course of several cell
divisions [36,44], and resulted in a higher percentage of pericytes
retaining the dye. Previous studies addressing the potential role of
HDAC inhibitors in blood vessel biology have focused on the
endothelium [24–29]. These in vitro results show that HDAC
inhibition has an anti-proliferative effect also on pericytes and
limits the expansion of the pericyte population over time.
The present investigation shows that HDAC inhibition perturbs
pericyte migration. When analyzing results from migration assays
cell proliferation and viability must be taken into account in that a
decrease in proliferation/viability may be misinterpreted as an
inhibition of migration. In the present investigation no significant
changes in the number of viable cells was seen after exposing
pericytes to the concentrations of VPA used in the migration assay.
Thus, cell death should not influence the observed results. At the
24-hour time point inhibitory effects on proliferation, but not
migration, were seen in pericytes exposed to 1 mM VPA. VPAs
inhibitory effect on migration was first significant in pericytes
exposed to 3 mM VPA. Thus, a decrease in pericyte proliferation
should not influence the observed results. The HDAC inhibitor
TSA had a similar effect on pericyte migration. No effect on
migration was observed when cells were exposed to the VPA
analogue Penta suggesting that HDAC inhibition and not ‘‘off
target effects’’ of VPA lead to the observed inhibition of pericyte
migration. The results show that HDAC inhibition inhibits
pericyte migration.
The present investigation shows that VPA induces and
upregulates expression of mRNAs coding for proteins involved
in angiogenesis in pericytes in vitro. HDAC inhibition has been
shown to inhibit angiogenesis in vivo and endothelial cell
proliferation in vitro [24–29]. No studies to our knowledge have
addressed the role of pericytes in HDAC mediated effects on
angiogenesis. Several pathological states in adults are initially
characterized by an excessive and aberrant angiogenesis. Vascular
regression and pruning followed by vascular maturation is
required for the finalization of tissue reparative processes [45–
48]. The qPCR data support that VPA induces a phenotype in
pericytes consistent with events that occur during the later stages of
angiogenesis i.e. vessel stabilization and maturation. Several of the
genes that were upregulated in pericytes exposed to VPA are
involved in endothelial cell survival (angiopoietin like 4 [49,50]
and IL-8 [51,52]), endothelial tube formation/stabilization/
branching (FGFR-3 [53–55] and integrin b3-subunit [56]),
formation and maintenance of direct cell-cell contacts between
endothelial cells and pericytes (TGF- b1 and 2 [57–59]), basement
membrane formation (laminin a5 [60] and collagen type 18
[45,57]) and inhibition of metalloprotease activity (TIMP 1 and 2
[61]). All of these events are consistent with vessel stabilization/
maturation [45]. A further support for this interpretation is that
genes only detected in pericytes exposed to VPA i.e. expression was
induced by VPA, included gene products involved in endothelial
survival, differentiation and fenestration (prokineticin 2 [62,63]
and stabilin-1 [64]) as well as angiostasis (Cxcl3 and 6 [65,66] and
epiregulin). Thus, we hypothesize that the observed inhibition of
proliferation and migration together with the mRNA expression
profile in response to VPA results in a pericyte phenotype
consistent with vessel stabilization/maturation.
The present investigation shows that exposure to VPA inhibits
differentiation of pericytes into pro-fibrotic connective tissue cells.
We have in previous studies demonstrated that pericytes with a
phenotypesimilartothatseeninvivocanbemaintainedinvitro[6–8].
Increasing evidence suggest that pericytes are capable of differen-
tiating into collagen type I producing fibroblasts both in vitro and in
vivo, thereby implicating the microvascular pericyte in the process of
fibrosis in a previously unrecognized way [6–13,67–70]. This
differentiation process was studied in vitro by examining shifts in the
expression of markers over time by flow cytometry [6–8]. VPA
increased the proportion of cells with a marker expression profile
consistent with the pericyte phenotype while decreasing the
proportion of cells with a marker profile expression characteristic
of fibroblasts. The results show that VPA inhibits the differentiation
ofpericytes intopro-fibroticcollagentypeI producingfibroblasts.In
support of this notion the proportion of cells expressing procollagen
type I a marker for collagen type I synthesis was decreased in
pericytes exposed to VPA. Previous in vitro and in vivo studies in for
instance liver, pancreas and kidney have shown that HDAC
inhibition is anti-fibrotic by reducing the proliferation and
activation of pro-fibrotic connective tissue cells and the production
of collagen type I [25,30–32,71–75]. However, the coupling of the
anti-fibrotic effects of HDAC inhibition to microvascular pericytes
has not previously been recognized. VPA is the first compound that
has been identified as being able to inhibit this differentiation
process. We speculate that the current results may in part explain
the anti-fibrotic effects of HDAC inhibition observed in vivo.
However, future studies will be required to address this issue.
The results suggest that HDACs may have a dual role in
pericyte behaviour. HDAC inhibition leads to appropriate
maturation/stabilization of vessels on the one hand and inhibition
of the development of pro-fibrotic connective tissue cells on the
other. Interestingly, gene deletion studies in mice show that PDGF
Table 1. Upregulation of angiogenesis related genes in
human pericytes exposed to 2 mM VPA.
Gene Protein p-value VPA v. NTC
ANGPTL4 Angiopoietin-like 4 0.042 46.76
EFNA3 Ephrin-A3 0.022 25.35
FGFR3 Fibroblast growth factor receptor 3 0.003 21.56
PTGS1 Prostaglandin-endoperoxide synthase 1 0.012 17.52
IL8 Interleukin 8 0.049 10.3
TYMP Thymidine phosphorylase 0.0005 10.06
ITGB3 Integrin beta3 (CD61) 0.018 9,55
TGFB2 Transforming growth factor beta2 0.023 9.07
TIMP1 TIMP metallopeptidase inhibitor 1 0.00006 8.41
LAMA5 Laminin alpha5 0.008 4.56
PLXDC1 Plexin domain containing 1 0.031 4.33
COL18A1 Collagen type XVIII alpha1 0.039 3.34
TGFB1 Transforming growth factor beta1 0.014 3.34
TIMP2 TIMP metallopeptidase inhibitor 2 0.016 2.57
Fold regulation of the expression of genes significantly altered in pericytes
exposed to 2 mM VPA for 3 days compared to NTC. P-value ,0.05 was
considered significant.
doi:10.1371/journal.pone.0024954.t001
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population during embryogenesis is crucial for expansion of the
fibroblast population in reactive connective tissue formation in
adults suggesting a common origin of these two cell-types [68,76].
Thus, the role of pericytes during embryogenesis compared to
wound healing processes in adults may be quite different. We
speculate that it would be advantageous for pericytes to behave
more ‘‘embryonic’’ in order to optimally generate and regenerate
tissues in the adult animal. Furthermore, that inhibiting the driving
forces that regulate pericyte differentiation to collagen type I
producing fibroblast will have a positive influence on limiting
fibrosis. Thus, modulating HDAC function may have a role in both
of these processes by affecting pericytes. In conclusion HDAC
inhibition through VPA affects microvascular pericyte function and
phenotypeandmayhave important ramificationsinlimiting fibrosis
while promoting tissue repair/regeneration following tissue injury
secondary to trauma and/or pathology. Future in vivo studies using
different types of HDAC inhibitors in pathologies as well as models
oftissueregeneration/repairwillberequiredtofurtherelucidatethe
dual effect of HDAC inhibition on pericytes and the potential for
optimal tissue repair/regeneration with minimal fibrosis.
Materials and Methods
Cell isolation and cell culture
Primary pericyte cultures from human placenta were isolated as
described previously [6] and maintained in growth media: RPMI
1640 (Gibco, CA, USA) containing 10% FCS (Saveen-Werner,
Sweden) and Penicillin/Streptomycin (SVA, Uppsala, Sweden).
All cell culture incubations were performed at 37uC in humidified
incubators with 5% CO2.
Ethics Statement
The acquisition of human placentas was approved by the
human ethics committee of the University of Uppsala, Sweden.
The placentas were anonymous and there was no personal data
collected on the donors.
Cytotoxicity
For cytotoxicity studies 5 000 pericytes per well were seeded onto
collagen type I (Vitrogen, CA, USA) coated (50 mg/ml for .1h )
96-well plates (Perkin-Elmer Inc. Wellesley, MA, USA) and grown
for 18 h before the addition of 1, 5 or 15 mM of VPA (P4543,
Sigma Aldrich, Sweden). RPMI 1640 containing 10% FCS was
used as a control (NTC). Plates were incubated for 72 h before the
cells were stained with the Multiparameter Cytotoxicity 1 Kit
(Cellomics Inc., PA, USA). Plates were read with the ArrayScan
high content screen system (Cellomics Inc.) and a cytotoxicity index
based on nuclear morphology/size, cell membrane permeability,
lysosomal mass-pH and cell density, was obtained according to the
manufacturers instructions.
Proliferation
Pericytes were seeded in 60 mm plates (Sarstedt, Germany) and
incubated for 24–48 hours in RPMI growth media. One day prior
to harvesting pericytes were exposed to different concentrations of
trichostatin A (TSA) purchased from Sigma Aldrich, VPA, and the
VPA analogue Penta (a kind gift from Heinz Nau at the University
of Veterinary Medicine, Hannover, Germany) or growth medium
with vehicle (DMSO). Four hours prior to harvesting 10 mM5 -
ethynyl-29-deoxyuridine (EdU), used as a proliferation marker,
detecting cells entering the S-phase of the cell cycle was added to
the cells. 10 minutes prior to harvesting 2.5 mg/ml propidium
iodide (Invitrogen, Eugene, Oregon, USA), used as a marker for
cell viability, was added. Cells were then washed, fixed in 4%
paraformaldehyd and processed according to the manufacturers
protocol for the ‘‘Click-iT EdU Pacific Blue Flow Cytometry Assay
Kit’’ (Invitrogen). Cells were then analyzed by flow cytometry
using a FACSAria (BD Biosciences, Sweden).
CFDA-SE assay
In the Carboxyfluorescein diacetate succinimidyl ester (CFDA-
SE) proliferation assay, cells are loaded with CFDA-SE that
spontaneously and irreversibly bind to cellular proteins by reacting
with lysine side chains and other available amines [36,44]. Cells
are then seeded into culture plates and for each cell division that
takes place CFDA-SE is distributed equally between the daughter
cells, which therefore have half the fluorescence intensity
compared to the parent cell. Thus, for each successive generation
in a population of proliferating cells a two-fold decrement in
cellular fluorescence intensity occurs that can be determined by
flow cytometry. The proliferating cell population can then be
studied over time and the number of cell divisions that have taken
place can be calculated allowing for cells to be followed over
several generations. Passage two pericytes were trypsinized and
collected in a pellet. The pellet was resuspended in RPMI 1640
containing 0.5 mM CFDA-SE and left at 37uC for 10 minutes.
RPMI 1640 containing 10% FCS was added and cells were
centrifuged at 200 rpm for 5 minutes. Cells were seeded in 6 well
plates in RPMI 1640 containing 10% FCS and 1 or 5 mM VPA.
RPMI 1640 containing 10% FCS with and without VPA was used
as control. After seven days of VPA exposure cells were trypsinized
and collected and analyzed by flow cytometry for the expression of
CFDA-SE.
Immunoblotting
Pericytes were cultured in 8-well plates with or without 1 mM
VPA for 30 min, 1 h, 12 h, 24 h, 3 d and 7 d. The cells were
solubilized in RIPA buffer (150 mM NaCl, 1% NP-40, 0,5%
deoxycholic acid, 0,1% SDS, 50 mM Tris pH 8.0) and protein
concentrations were quantified using the 2D-Quant kit (GE
Healthcare, Uppsala, Sweden). Western blot using an H4K5/8/
12/16ac antibody (dilution 1:3000) (06-866,Upstate Biotechnology)
was performed using the ECL Advance western blotting detection
system (GE Healthcare) according to the manufacturers guidelines.
Briefly, 10 mg of the protein samples were separated by the BioRad
mini-Protean system on a 12.5% SDS-PAGE gel using Laemmeli
buffer (25 mM Tris, 192 mM Glycine and 0,1% SDS) as a running
buffer. The proteins were then transferred to 0.45 mm nitrocellulose
membrane (Hybond ECL, GE Healthcare) in a blotting cassette
(BioRad mini-Trans-Blot cell) followed by incubation with the
primary antibody and then the secondary antibody (Santa Cruz,
CA, USA) conjugated to horseradish peroxidase (HRP). The
immunoblots were exposed to Cronex 5 light sensitive film.
Migration assay
Cells were seeded into 24-well plates at 20 000 cells/cm
2 and
were allowed to attach for 12 h in RPMI 1640 containing 10%
FCS. A uniform scratch, using a 200 ml pipette, was afflicted in the
middle of each well creating an area devoid of cells (Figure 3A).
These pericyte cultures were then exposed to RPMI 1640 medium
containing 10% FCS and VPA, TSA or Penta or vehicle for
24 hours. RPMI 1640 medium containing 10% FCS without VPA
was used as control. Semi-quantifications of the extent of pericyte
migration into the cellular gap/void over time were performed.
Each treatment group was observed in four replicates. The
individual migration score can either be 0 (no migration at all), 1
(migration initiated along the border but pericytes do not spanning
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but not completely populating the gap/void), and 3 (migrating
pericytes have completely repopulated the gap/void) [37]. The
average score of replicates/groups is calculated and compared.
Differentiation
Passage two pericytes were seeded in 6-well plates and exposed
to 1 or 2 mM VPA in RPMI 1640 containing 10% FCS for
72 hours. RPMI 1640 containing 10% FCS was used as controls.
After 72 hours cells were trypsinized and labeled with antibodies
against the pericyte marker CD146 (mAb24577, Abcam, UK)
[41,42]; the fibroblast markers; Fibroblast surface protein (mAb
FSP) (F771, SigmaAldrich) [43] and procollagen type I
(pAb64409, Abcam, United Kingdom); and a-smooth muscle
actin (mAb a-SMA, F3777, Sigma Aldrich) a marker expressed by
both pericytes and fibroblasts [9,38–40]. Cells were labeled in PBS
containing 0.2% BSA for 20 minutes on ice, washed twice with
PBS containing 0.2% BSA before a 20 minute incubation on ice
with the secondary antibody diluted in PBS containing 0.2% BSA
(Allophycocyanin-goat anti mouse IgG (115-136-072, Jackson
Immuno Research, UK), FITC-goat anti mouse IgM (115-096-
075, Jackson Immuno Research) or FITC-rat anti mouse IgG (FI-
4000, Vector Laboratories Inc, CA, USA). Cells were then washed
two times before being analyzed by flow cytometry on a FACSAria
flow cytometer (BD Biosciences). Isotype Mouse IgG (I-8765,
Sigma Aldrich, Sweden), IgM (ab 18401, Abcam, UK), and rat
IgG were used as controls and to determined background levels of
staining intensity. Based on controls cells were either positive or
negative for the expression of each marker. Several sets of 10,000
cells were analyzed. The relative expression i.e. the number of cells
positive for each marker was determined and compared between
the different conditions. Experiments were performed on cells
isolated from three different placentas.
Angiogenesis quantitative PCR array
RNA was extracted from cultured pericytes after three days of
culture in 24-well plates (starting with ,3610
5 cells per well) in
RPMI 1640 medium containing 10% FCS with or without 2 mM
VPA. The cells were washed twice with cold PBS before being lysed
directly in the well with b-mercaptoethanol containing lysis buffer
provided in the RNeasy Mini kit (QIAGEN, Denmark), followed by
the use of QIA shredder spin columns (QIAGEN). Subsequent
RNA preparation was done according to the protocol for the
RNeasy Mini kit. RNA concentration was determined by the use of
a NanoDrop ND-1000 Spectrophotometer (Nanodrop Technolo-
gies, DE, USA), and quality control was done with the Experion
system and RNA StdSens chips (Bio-Rad, CA, USA). cDNA
synthesis based on 0.33 mg total RNA per sample was performed
using the RT
2 First Strand Kit (SA Biosciences, MD, USA). Real-
time PCR was performed on an iCyclerIQ (Bio-Rad) using the RT
2
qPCR SYBR green mastermix and Human Angiogenesis RT
2
Profiler PCR 96-well Arrays (Catalogue number PAHS-024A, SA
Biosciences) [77] and the recommended PCR cycling program
(10 min 95uC (1 cycle), 15 s 95uCp l u s6 0s6 0 uC (40 cycles)) [77].
See gene symbols and their corresponding descriptions in Table S1.
The total volume of the PCR was 25 ml. Samples were run in a
randomized order to prevent any technical and design bias. The
PCR array data passed the SA Biosciences online quality control.
Data analysis of relative gene expression was performed using the
DDCt method with HPRT1, RPL13A and GAPDH as housekeep-
ing genes. Fold change values and Students t-test p-values were
exported from SA Biosciences PCR array analysis web service
(www.sabiosciences.com/pcrarraydataanalysis.php). DCt values
were exported from the SA biosciences PCR array data analysis
web portal for further analysis. General properties in the data set
were visualized using hierarchical clustering (complete linkage and
Euclidian distance) in the R software (version 2.11). Top candidate
genes were searched against the STRING protein-protein interac-
tion database (version 8.3, http://string.embl.de/). The resulting
network data was expanded with the addition of 10 more gene/
protein partners known to interact with the top candidates but not
part of the qPCR genes to connect separate clusters. Network data
was exported and visualized in the Cytoscape software. Interaction
score strength based on STRING criteria was defined as either
.0.9 or ,0.9 (1.0 being the top score). The analysis is based on the
isolation of pericytes from 4 different placentas
Data analysis
All data are shown as mean 6 SD. Comparisons between two
groups were analyzed using unpaired Students t-test. A P value
,0,05 was considered to be statistically significant. All experi-
ments were performed at least in triplicates.
Supporting Information
Table S1 Gene symbols and gene description included
in the qPCR array. Information derived from the manufacturer
of the array (Catalogue number PAHS-024A, SA Biosciences).
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